Market news
Detailed price information for Precipio Inc (PRPO-Q) from The Globe and Mail including charting and trades.
Detailed price information for Fulgent Genetics Inc (FLGT-Q) from The Globe and Mail including charting and trades.
Fulgent Genetics (NASDAQ:FLGT) reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Bako Diagnostics and StrataDx. Management also lowered its full-year revenue outlook, citing lower co
EL MONTE, Calif., July 30, 2026--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2026.
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -26.09% and -9.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Despite billing system transition challenges and revised guidance, Fulgent Genetics advances its clinical pipeline and expands its AI-driven diagnostics portfolio.
This is the newest page. Registered accounts read further back.